Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials

OBJECTIVES: To evaluate the risk of psychiatric disorders and all-cause mortality associated with belimumab therapy in patients with SLE. METHODS: A literature search of four electronic bibliographic databases, including PubMed, EMBASE, Scopus and Cochrane databases, was conducted for randomised con...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Wenhui, Huang, Hong, Zhan, Siyan, Zhang, Zhuoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Epidemiology and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547509/
https://www.ncbi.nlm.nih.gov/pubmed/34697129
http://dx.doi.org/10.1136/lupus-2021-000534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547509/
https://www.ncbi.nlm.nih.gov/pubmed/34697129
http://dx.doi.org/10.1136/lupus-2021-000534

Ejemplares similares